- Home
- BWB vs BCYC Comparison
BWB vs BCYC Comparison
Compare BWB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- BCYC
- Stock Information
- Founded
- BWB 2005
- BCYC 2009
- Country
- BWB United States
- BCYC United Kingdom
- Employees
- BWB N/A
- BCYC N/A
- Industry
- BWB Major Banks
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- BCYC Health Care
- Exchange
- BWB Nasdaq
- BCYC Nasdaq
- Market Cap
- BWB 442.3M
- BCYC 492.1M
- IPO Year
- BWB 2018
- BCYC 2019
- Fundamental
- Price
- BWB $16.68
- BCYC $6.93
- Analyst Decision
- BWB Strong Buy
- BCYC Buy
- Analyst Count
- BWB 2
- BCYC 11
- Target Price
- BWB $20.00
- BCYC $22.91
- AVG Volume (30 Days)
- BWB 43.5K
- BCYC 233.2K
- Earning Date
- BWB 10-22-2025
- BCYC 10-30-2025
- Dividend Yield
- BWB N/A
- BCYC N/A
- EPS Growth
- BWB 12.01
- BCYC N/A
- EPS
- BWB 1.21
- BCYC N/A
- Revenue
- BWB $119,312,000.00
- BCYC $19,281,000.00
- Revenue This Year
- BWB $35.51
- BCYC N/A
- Revenue Next Year
- BWB $11.83
- BCYC $0.27
- P/E Ratio
- BWB $13.69
- BCYC N/A
- Revenue Growth
- BWB 12.23
- BCYC N/A
- 52 Week Low
- BWB $11.93
- BCYC $6.10
- 52 Week High
- BWB $17.66
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- BWB 59.02
- BCYC 40.24
- Support Level
- BWB $16.30
- BCYC $6.84
- Resistance Level
- BWB $16.69
- BCYC $7.32
- Average True Range (ATR)
- BWB 0.35
- BCYC 0.36
- MACD
- BWB 0.03
- BCYC 0.01
- Stochastic Oscillator
- BWB 98.72
- BCYC 20.16
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.